Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Optinose Inc (NQ: OPTN )

4.190 USD -0.050 (-1.18%)
Official Closing Price Updated: 4:23 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Optinose Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags Top Stories AKAO ZGNX
From Benzinga
OPTN: Insiders vs. Shorts
The most recent short interest data was recently released for the 06/15/2018 settlement date, and OptiNose Inc (OPTN) is one of the most shorted stocks of the Russell 3000, based on 5.65 "days to... 
Tags Stocks
From Market News Video
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the... 
From GlobeNewswire News Releases
Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags ARLZ VRTX CRIS
From Benzinga
Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that results of the Phase 3 NAVIGATE II trial and the... 
From GlobeNewswire News Releases
Insiders Seeing Green With OPTN At New 52-Week High
In trading on Thursday, shares of OptiNose Inc (OPTN) touched a new 52-week high of $25.76/share. That's a 71.62% rise, or $10.75 per share from the 52-week low of $15.01 set back on 11/14/2017.. 
Tags Stocks
From Market News Video
Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The Year 2018 in Greater
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller and President and Chief... 
From GlobeNewswire News Releases
Investors Grab OPTN Even Cheaper Than Its Secondary Stock Offering
Looking back to 6 days ago, OptiNose Inc (OPTN) priced a 5,000,000 share secondary stock offering at $22.25 per share. Buyers in that offering made a considerable investment into the company, expecting... 
Tags Stocks
From Market News Video
Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares
OptiNose, Inc. (NASDAQ:OPTN), announced today the closing of its underwritten public offering of 5,750,000 of its common shares at a price to the public of $22.25 per common share, including 750,000... 
From GlobeNewswire News Releases
Optinose Announces Pricing of Public Offering of Common Stock
OptiNose, Inc. (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting... 
From GlobeNewswire News Releases
Optinose Announces Launch of Public Offering of Common Stock
OptiNose, Inc. (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public... 
From GlobeNewswire News Releases
Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags SPHS News BIOL
From Benzinga
Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31,... 
From GlobeNewswire News Releases
Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018
Conference Call and Webcast Scheduled for Monday, May 14 at 8:00 a.m. Eastern Time 
From GlobeNewswire News Releases
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller and President/COO Ramy Mahmoud,... 
From GlobeNewswire News Releases
Investors Should Opt Out Of OptiNose Before IPO Lock-Up Expires
When the 180-day lock-up period for OptiNose, Incorporated (OPTN) ends on April 11, 2018, the company's pre-IPO shareholders and insiders will have the ability to sell large blocks of... 
Tags Healthcare Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
Drug companies are beginning to wake up to this new risk factor
New programs that target coupons for expensive medications have taken off. 
Tags SNY AT:UCB Company Announcements
From MarketWatch
Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinose was named the Emerging Company of the... 
From GlobeNewswire News Releases
Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended... 
From GlobeNewswire News Releases
Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018
Conference Call and Webcast Scheduled for Tuesday, March 13 at 8:00 a.m. Eastern Time 
From GlobeNewswire News Releases
Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress
Optinose expects to make XHANCE (fluticasone propionate) nasal spray 93mcg available through retail pharmacies in early April 2018 
From GlobeNewswire News Releases
Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Sandra L. Helton as... 
From GlobeNewswire News Releases
Peter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania
Optinose Also Named as Finalist for Emerging Company of the Year 
From GlobeNewswire News Releases
Analysts See 10% Gains Ahead For IWV
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
OptiNose Becomes Oversold (OPTN)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Optinose to Present at the 2018 RBC Capital Markets Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will... 
From GlobeNewswire News Releases
Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will... 
From GlobeNewswire News Releases
Optinose Announces $100 Million Debt Financing from Athyrium Capital Management
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a $100 million debt... 
From GlobeNewswire News Releases
40 Biggest Movers From Yesterday
Gainers Proteostasis Therapeutics Inc (NASDAQ: PTI) shares climbed 161.28 percent to close at $6.14 on Tuesday after the ... 
Tags OMED SYRS NCS
From Benzinga
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.